Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenofovir alafenamide
- Development stage
- Approved
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tenofovir alafenamide is a small molecule antiviral prodrug in the class of nucleoside reverse transcriptase inhibitors. It is used primarily for the treatment of chronic hepatitis B virus infection and as a component in fixed-dose combinations for HIV-1 treatment and prevention. Tenofovir alafenamide is an alanine ester prodrug that delivers high intracellular concentrations of its active metabolite, tenofovir diphosphate, while maintaining lower plasma levels compared to its predecessor, tenofovir disoproxil fumarate. This results in improved renal and bone safety profiles. The drug inhibits viral reverse transcriptase by acting as a chain terminator during viral DNA synthesis, thereby blocking replication in both HBV and HIV-1[1][3][4][8]. Tenofovir alafenamide was developed by Gilead Sciences.
- Brand names
- VemlidyDescovyOdefseyBiktarvyGenvoyaSymtuza
- Other names
- tenofovir alafenamide fumarateTAF
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseGag-Pol (HIV-1 gag-pol polyprotein)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on tenofovir alafenamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenofovir alafenamide.